Orforglipron News — every source, one live feed

Track Orforglipron news in real time — Lilly's daily weight-loss pill approaching approval and mass availability. fllwup^ collects the latest Orforglipron headlines from every major source into one live feed — free, no account, no algorithm. Coverage aggregated from BBC, Reuters, AP, NYT, TechCrunch, Al Jazeera, and 200+ other outlets.

Latest Orforglipron headlines

  • Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China — Reuters
  • Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease — Eli Lilly
  • Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss — PR Newswire
  • newsGP - New oral GLP-1 to hit Australian shelves within days — Royal Australian College of General Practitioners (RACGP)
  • Doctors can now prescribe Australia’s second oral GLP-1 drug — AusDoc
  • Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison — Eli Lilly
  • Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — Eli Lilly
  • Switching From Injectable to Oral GLP-1 Agents | Metabolic Care Today — DocWireNews
  • Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss — Eli Lilly
  • Orforglipron News: Foundayo FDA Approved for Weight loss — GoodRx

Follow Orforglipron live on fllwup^ · Follow in any RSS reader — or browse all topics.

Also tracking

More Health & Medicine: browse the category. Compare: fllwup^ vs Flipboard · vs Feedly · vs Google News · vs Apple News.